Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P48651

UPID:
PTSS1_HUMAN

ALTERNATIVE NAMES:
Serine-exchange enzyme I

ALTERNATIVE UPACC:
P48651; B4DE85; E5RFC5; Q9BUQ5

BACKGROUND:
Serine-exchange enzyme I, or Phosphatidylserine synthase 1, is pivotal in modifying the polar head group of phospholipids within the cell membrane. This enzyme's activity is essential for maintaining the balance of phospholipids, crucial for cell viability and function.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in phospholipid metabolism and its link to Lenz-Majewski hyperostotic dwarfism, Phosphatidylserine synthase 1 presents a promising avenue for drug discovery. Targeting this protein could lead to innovative treatments for related skeletal and developmental disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.